<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Deflazacort is the most commonly prescribed <z:chebi fb="0" ids="50858">corticosteroid</z:chebi> for the treatment of Duchenne <z:hpo ids='HP_0003560'>muscular dystrophy</z:hpo> in Canada </plain></SENT>
<SENT sid="1" pm="."><plain>We review the long-term experience with deflazacort treatment at two centers in Canada; Montreal and Toronto </plain></SENT>
<SENT sid="2" pm="."><plain>Deflazacort has benefitted both cohorts by prolonged ambulation, preserved cardiac and respiratory function, less <z:hpo ids='HP_0002650'>scoliosis</z:hpo> and improved survival </plain></SENT>
<SENT sid="3" pm="."><plain>Common side effects in both cohorts include <z:mp ids='MP_0005456'>weight gain</z:mp>, <z:mp ids='MP_0001255'>decreased height</z:mp> and <z:hpo ids='HP_0000518'>cataract</z:hpo> formation </plain></SENT>
<SENT sid="4" pm="."><plain>The Canadian experience supports the use of deflazacort in treating boys with Duchenne <z:hpo ids='HP_0003560'>muscular dystrophy</z:hpo> </plain></SENT>
</text></document>